-
Mashup Score: 5
Intravesical immunotherapy with Bacillus Calmette-Guérin (BCG) has been the standard of care for patients with high-risk non non–muscle invasive bladd…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3MSKCC Urologic Oncology Fellowship - 3 year(s) ago
Open House 2021
Source: Google DocsCategories: Latest Headlines, Oncologists1Tweet-
RT @UrologyMSK: Our Fellowship virtual open house is *ONE WEEK* from today (11/10/21) at 7pm — sign up here: https://t.co/h6yVi2rdDA Come…
-
-
Mashup Score: 3Urologic Oncology Fellowship - 3 year(s) ago
The fellowship is structured to provide a two year experience in research and clinical training. The fellowship is the largest and oldest of its kind in the world.
Categories: Latest Headlines, Oncologists1Tweet-
More details on our @sloan_kettering @SUO_YUO fellowship here: https://t.co/V7sNFiuZg8 https://t.co/ioG5FqTNDk
-
-
Mashup Score: 0
A retrospective cohort study of patients with “primary” and “secondary” muscle-invasive bladder cancer (MIBC) treated with chemotherapy before surgical removal of the bladder identified lower response rates and shorter survival in patients with secondary MIBC. Tumor genetic sequencing of separate di …
Source: PubMedCategories: Latest Headlines, Oncologists1Tweet-
MSKCC study was fairly restrictive in looking at clinical/biologic differences between primary & secondary MIBC tumors specifically to 3-4 cycles of cisplatin-based NAC (hypothesis: clonal selection from prior BCG selects for chemo-resistant cells) 2/ https://t.co/KCrTo1pd9y
-
-
Mashup Score: 0
Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014
Source: PubMedCategories: Latest Headlines, Oncologists1Tweet-
Our main genomic findings was that cisplatin-sensitizing ERCC2 mutations were enriched in primary MIBC, yet some data suggests ERCC2 mutations are not associated with response to carboplatin 9/ https://t.co/gOiRj6pQwq https://t.co/vof4EvHHDS
-
-
Mashup Score: 0
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations – Full Text View.
Source: clinicaltrials.govCategories: Latest Headlines, Oncologists1Tweet-
Analysis of prospective data from SWOG S1314, A031701, etc. should provide more definitive answers to whether differences between primary & secondary MIBC truly exist & how this should effect treatment recommendations @IyerGopa 12/ https://t.co/qSU4AzbH4N
-
-
Mashup Score: 0
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
@bbmdmsk @alvincgoh @bca_md @EKChaMD @h_alahmadie @UrologyMSK https://t.co/GpLVkDfLaP
-
Outstanding review on immunotherapy in NMIBC #bladdercancer by star @SUO_YUO fellow @CChuMD @UrologyMSK @MSKCancerCenter @BladderCancerUS A few take-homes and thoughts: 1/n https://t.co/P2E7ntpExa